The short answer
ACCOMPLISH-1 and ACCOMPLISH-2 are the two Phase 3 trials of aleniglipron, an oral non-peptide GLP-1 receptor agonist. Together they plan to enrol 4,700 participants across three maintenance dose arms and placebo, with primary completion for both trials in September 2028.
Key facts
- Compound
- Aleniglipron (GSBR-1290), oral small-molecule GLP-1 receptor agonist
- Sponsor
- Structure Therapeutics
- ACCOMPLISH-1
- NCT07654361, 3,600 participants, obesity or overweight with a comorbidity
- ACCOMPLISH-2
- NCT07654374, 1,100 participants, obesity or overweight with type 2 diabetes
- Design
- Randomised, placebo-controlled, triple-masked, four arms
- Dose arms
- 45 mg, 90 mg, 180 mg or placebo
- Titration
- 2.5 mg starting dose, 4-week increments
- Primary endpoint
- Percent change in body weight from baseline
- Primary completion
- September 2028 for both
What has started
Structure Therapeutics reported in August 2026 that the first patients had been dosed in the Phase 3 ACCOMPLISH programme for aleniglipron. The registry shows two trials. NCT07654361 began on 13 July 2026 and plans 3,600 participants with obesity or overweight and a weight-related comorbidity. NCT07654374 began on 17 July 2026 and plans 1,100 participants with obesity or overweight and type 2 diabetes. Both are recruiting, both are triple-masked and placebo-controlled, and both carry percent change in body weight from baseline as the primary endpoint with primary completion in September 2028.
The design, stated as registered
Each trial randomises to one of four arms: three maintenance doses of aleniglipron or placebo. The company describes those doses as 45 mg, 90 mg and 180 mg, with treatment beginning at a 2.5 mg starting dose and increasing in four-week increments. A starting dose seventy-two times below the highest maintenance dose is a substantial titration ladder, and it is the standard answer to the gastrointestinal tolerability problem that defines this class. These are dose arms in registered trials conducted under clinical supervision and are recorded here as facts about the trials.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The acronym is in one record and not the other
NCT07654374's official title ends '(ACCOMPLISH-2)'. Its structured acronym field is empty. NCT07654361, the larger and, for a weight-management indication, more consequential of the two,carries the ACCOMPLISH name in neither its acronym field nor its official title, whose text is purely descriptive. So the trial that most coverage will refer to as ACCOMPLISH-1 cannot be found in the registry by that name at all. This is now a documented pattern rather than an isolated slip: the same thing occurs across the VESPER programme for a different sponsor, where two Phase 3 records similarly carry press-attributed names the registry does not hold.
Why the omission has practical consequences
Registry search matches structured fields. A trial acronym that lives only in press releases, or only in free-text title, does not surface when someone tries to check a claim attached to that name. The downstream effect is that readers who try to verify a statement about ACCOMPLISH-1 find nothing, and reasonably conclude either that the trial does not exist or that they have searched wrong. The reliable route is always the same: find the NCT number and verify against that, because the NCT number is the only identifier guaranteed to be unique, stable and searchable.
What the programme is testing that the Phase 2 work could not
Aleniglipron's Phase 2 data is encouraging and small. ACCESS enrolled 230 adults over 36 weeks and ACCESS II enrolled 85 over 44 weeks. The step to 3,600 and 1,100 participants over a longer horizon is what pivotal evidence requires, and the reasons are as much about safety as efficacy. A chronically dosed weight-management drug needs an exposure database large enough to characterise uncommon events. The separate diabetes trial matters too: efficacy in weight management and efficacy on glycaemic control in people with type 2 diabetes are different claims requiring different evidence, and running them in parallel is how a sponsor supports both.
What this does not mean
Aleniglipron is investigational. It is not licensed in any jurisdiction, it is not available on prescription, and it is not supplied on this site in any form. Starting Phase 3 is a statement about a development programme, not about efficacy or safety; the trials exist because the questions are open. Anyone considering treatment for obesity should be discussing licensed options with a clinician, and research material is never an alternative to a licensed medicine.
Quick reference
| ACCOMPLISH-1 | ACCOMPLISH-2 | |
|---|---|---|
| Registration | NCT07654361 | NCT07654374 |
| Acronym in registry | Nowhere | Official title only |
| Planned enrolment | 3,600 | 1,100 |
| Population | Obesity/overweight with comorbidity | Obesity/overweight with type 2 diabetes |
| Start date | 13 July 2026 | 17 July 2026 |
| Primary completion | September 2028 | September 2028 |
Frequently asked questions
How does this compare with the size of other Phase 3 obesity programmes?
It is in the normal range. Berobenatide's VESPER-4 plans 3,578 participants and its diabetes trial 1,044, which is close to the same split. Pivotal obesity programmes run into the thousands because of the safety database expected for chronic dosing in a large population, not because detecting a weight difference is hard.
When will results be available?
Primary completion for both trials is September 2028. Topline reporting typically follows some months after that, and full publication later still. Any figure quoted before then comes from earlier-phase work.
Is aleniglipron the same as orforglipron?
No. Both are oral non-peptide GLP-1 receptor agonists, which is a shared mechanism and a shared administration route, not a shared molecule. Orforglipron is licensed; aleniglipron is investigational, and its Phase 3 evidence does not yet exist.
Why does the registry say triple-masked when the sponsor says double-blind?
The registry field records how many parties are masked, typically participant, care provider, investigator and outcomes assessor in some combination,and 'double-blind' in ordinary usage does not map cleanly onto it. The registry entry is the more precise statement.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- A Warning Comes Off Three GLP-1 LabelsOn 13 January 2026 the FDA asked manufacturers to remove the suicidal ideation warning from Saxenda, Wegovy and Zepbound, citing 91 randomised trials.
- A Muscle Trial That Changed Its Primary EndpointVeru's QUALITY trial measured lean body mass. Its successor PLATEAU measures total body weight, which is a different question about the same combination.
- Four Arms, and Where the Participants WentREDEFINE 1 randomised 3,417 adults to CagriSema, semaglutide alone, cagrilintide alone or placebo. Its allocation ratio says what it was designed to answer.
- Less Weight Loss, and That Is the Expected ResultREDEFINE 2 reported a -13.7% weight change in adults with type 2 diabetes, against -20.4% in the trial without diabetes. That gap is a well-documented pattern.
- Superior to Semaglutide, by 0.16 Percentage PointsREIMAGINE 2 made semaglutide its primary comparator rather than placebo. The combination won, and the size of that win is the part actually worth reading.